Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children

2006/12/04 by Jeffrey Hyams, Jeffrey S. Hyams, Wallace Crandall +19 · 26 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Inflammatory Bowel Disease #Rheumatoid Arthritis Research and Therapies #Celiac Disease Research and Management

paper · pdf · doi:10.1053/j.gastro.2006.12.003

Cited by

• Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children
• Increased immune reactivity predicts aggressive complicating Crohn's disease in children. [europepmc]
• Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. [europepmc]
• Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. [europepmc]
• Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. [europepmc]
• Predicting response to Anti-TNF Agents for the treatment of crohn's disease. [europepmc]
• Natural history of pediatric-onset inflammatory bowel disease: a systematic review. [europepmc]
• Crohn's and colitis in children and adolescents. [europepmc]
• Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. [europepmc]
• Infliximab-Related Infusion Reactions: Systematic Review. [europepmc]
• Inflammatory Bowel Disease in Children and Adolescents. [europepmc]
• Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. [europepmc]
• Diagnosis and management of inflammatory bowel disease in children. [europepmc]
• Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. [europepmc]
• Can We Predict the Efficacy of Anti-TNF-α Agents? [europepmc]
• A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. [europepmc]
• Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. [europepmc]
• Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. [europepmc]
• Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD. [europepmc]
• North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease. [europepmc]
• Infliximab in young paediatric IBD patients: it is all about the dosing. [europepmc]
• Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? [europepmc]
• Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. [europepmc]
• First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. [europepmc]
• Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease. [europepmc]
• Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. [europepmc]